Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS: Neoadjuvant chemotherapy followed by surgery and postoperative chemotherapy vs chemoradiotherapy in resectable gastric cancer
2006-004130-32Phase 3Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin, capecitabine and epirubicin in gastric cancer (GC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Started Aug 2006; status: active.
02
Drugs
cisplatincapecitabineepirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on 2006-004130-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004130-32.